We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Breaking the Brake: How Annexin A2 Inhibition Restores Mitophagy and Salvages the Infarcted Heart

MedXY Editorial Team•Mar 25, 2026•Cardiology
Annexin A2mitophagymyocardial infarctionPHB2

Highlights

1. Annexin A2 (ANXA2) is significantly upregulated in human and murine ischemic hearts, and its circulating levels correlate with the severity of acute myocardial infarction (MI).

2. ANXA2 acts as a molecular brake on mitophagy by competitively binding to the receptor Prohibitin 2 (PHB2), preventing its interaction with LC3B.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Targeting the CCND1-PDK4 Axis to Promote Reparative Macrophage Phenotype and Mitigate Post-Myocardial Infarction Cardiac RemodelingThis article discusses the role of cyclin D1 (CCND1) in promoting reparative macrophage transition post-myocardial infarction, highlighting its therapeutic potential in reducing adverse cardiac remodeling through metabolic reprogramming.Sep 19, 2026Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D TrialThe TARGET-D trial investigated whether vitamin D supplementation, titrated to achieve serum levels >40-80 ng/mL, reduces major adverse cardiovascular events after myocardial infarction but found no significant benefit in the primary comSep 17, 2026Comparing 0/1-Hour vs 0/3-Hour High-Sensitivity Troponin Pathways for Suspected Acute Coronary Syndrome in Real-World PracticeThis randomized trial evaluates the safety and efficiency of the ESC 0/1-hour versus 0/3-hour high-sensitivity troponin pathways in suspected acute coronary syndrome, showing noninferior safety but no significant improvement in rapid dischaSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Stent Retriever Thrombectomy Reduces Infarct Size in High-Thrombus Myocardial Infarction: Insights from the NATURE Trial
The NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.
Sep 6, 2026
Refining Myocardial Infarction Diagnosis: A Novel Causal Endotype-Based Classification Beyond Type 1 and Type 2 MIThis study introduces a causal endotype-based classification of myocardial infarction, revealing distinct underlying mechanisms and clinical outcomes beyond the traditional type 1/type 2 framework, potentially improving MI diagnosis and manSep 1, 2026
Evolving Impact of Implantable Cardioverter-Defibrillators on Mortality Post-Myocardial Infarction: Insights from the PROFID StudyThe PROFID study reveals a declining mortality benefit from primary prevention implantable cardioverter-defibrillators in post-myocardial infarction patients with reduced ejection fraction over recent decades, highlighting changing clinicalAug 29, 2026